MX2019007360A - Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. - Google Patents
Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.Info
- Publication number
- MX2019007360A MX2019007360A MX2019007360A MX2019007360A MX2019007360A MX 2019007360 A MX2019007360 A MX 2019007360A MX 2019007360 A MX2019007360 A MX 2019007360A MX 2019007360 A MX2019007360 A MX 2019007360A MX 2019007360 A MX2019007360 A MX 2019007360A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- preparation
- azabicyclo
- triazole derivative
- substituted triazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
La presente invención se refiere a un derivado de triazol azabiciclo-sustituido, a un método de preparación del mismo, y a una aplicación del mismo en medicina. En particular, la presente invención se refiere a un nuevo derivado de triazol azabiciclo-sustituido representado por la fórmula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el derivado, un uso del mismo como agente terapéutico, especialmente como un antagonista de la oxitocina, y un uso del mismo en la preparación de un fármaco para tratar o prevenir una enfermedad o trastorno conocido o demostrado tener un efecto benéfico sobre el mismo con la supresión de la oxitocina. La definición de cada sustituyente en la fórmula general (I) es la misma que la definición en la especificación.(ver formula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611233476 | 2016-12-28 | ||
| PCT/CN2017/118784 WO2018121551A1 (zh) | 2016-12-28 | 2017-12-27 | 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007360A true MX2019007360A (es) | 2019-08-16 |
Family
ID=62710083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007360A MX2019007360A (es) | 2016-12-28 | 2017-12-27 | Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210040073A1 (es) |
| EP (1) | EP3564231A4 (es) |
| JP (1) | JP2020504109A (es) |
| CN (2) | CN113149961B (es) |
| AU (1) | AU2017389819B2 (es) |
| CA (1) | CA3047641A1 (es) |
| MX (1) | MX2019007360A (es) |
| TW (1) | TW201823231A (es) |
| WO (1) | WO2018121551A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020001460A1 (zh) * | 2018-06-27 | 2020-01-02 | 江苏恒瑞医药股份有限公司 | 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法 |
| CN113004250B (zh) * | 2019-12-19 | 2022-07-26 | 上海森辉医药有限公司 | 一种制备取代的三唑衍生物的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| BRPI0414663A (pt) | 2003-09-22 | 2006-11-21 | Pfizer | derivados triazol substituìdos como antagonistas de oxitocina |
| WO2005082866A2 (en) | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| AP2007004047A0 (en) * | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| JP2008533192A (ja) * | 2005-03-21 | 2008-08-21 | ファイザー・リミテッド | オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体 |
| US20080214622A1 (en) * | 2005-03-21 | 2008-09-04 | Alan Daniel Brown | Substituted Triazole Derivatives As Oxytocin Antagonists |
| CA2618103A1 (en) * | 2005-08-10 | 2007-02-15 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| EP2078016B1 (en) | 2006-10-19 | 2012-02-01 | Signal Pharmaceuticals LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| CN102372701A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用 |
| CN106536489B (zh) | 2014-05-28 | 2020-02-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 类视黄醇相关孤儿受体γ调节剂及其用途 |
-
2017
- 2017-12-27 WO PCT/CN2017/118784 patent/WO2018121551A1/zh unknown
- 2017-12-27 TW TW106145996A patent/TW201823231A/zh unknown
- 2017-12-27 CN CN202110204338.9A patent/CN113149961B/zh active Active
- 2017-12-27 US US16/472,527 patent/US20210040073A1/en not_active Abandoned
- 2017-12-27 AU AU2017389819A patent/AU2017389819B2/en not_active Ceased
- 2017-12-27 JP JP2019533376A patent/JP2020504109A/ja not_active Withdrawn
- 2017-12-27 MX MX2019007360A patent/MX2019007360A/es unknown
- 2017-12-27 CA CA3047641A patent/CA3047641A1/en not_active Abandoned
- 2017-12-27 CN CN201780020566.2A patent/CN109071492B/zh active Active
- 2017-12-27 EP EP17885670.4A patent/EP3564231A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW201823231A (zh) | 2018-07-01 |
| CN113149961A (zh) | 2021-07-23 |
| CA3047641A1 (en) | 2018-07-05 |
| US20210040073A1 (en) | 2021-02-11 |
| EP3564231A4 (en) | 2020-08-12 |
| CN109071492B (zh) | 2021-02-26 |
| EP3564231A1 (en) | 2019-11-06 |
| WO2018121551A1 (zh) | 2018-07-05 |
| AU2017389819B2 (en) | 2021-05-27 |
| CN109071492A (zh) | 2018-12-21 |
| AU2017389819A1 (en) | 2019-06-20 |
| JP2020504109A (ja) | 2020-02-06 |
| CN113149961B (zh) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| PH12017500281B1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
| MX2015010971A (es) | Derivado novedoso de pirazol. | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| NZ711424A (en) | Pyridine derivatives as soft rock inhibitors | |
| MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
| MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
| WO2015155680A3 (en) | Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors | |
| MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. | |
| MX2019007360A (es) | Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. | |
| MX2017008072A (es) | Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds |